Deep learning convolutional neural network ResNet101 and radiomic features accurately analyzes mpMRI imaging to predict MGMT promoter methylation status with transfer learning approach

• Published in: International journal of imaging systems and technology Vol. 34; no. 2
• Main Authors: Shim, Seong‐O, Hussain, Lal, Aziz, Wajid, Alshdadi, Abdulrahman A., Alzahrani, Abdulrahman, Omar, Abdulfattah
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01-03-2024; Wiley Subscription Services, Inc
• Subjects: Accuracy; Artificial neural networks; Brain; Brain cancer; brain tumor; Classification; convolution neural network; Datasets; Deep learning; feature selection method; Machine learning; Magnetic resonance imaging; Medical imaging; Methylation; Performance evaluation; Prognosis; radiomic features; Radiomics; Sensitivity; Tumors
• ISSN: 0899-9457; 1098-1098
• DOI: 10.1002/ima.23059

Accurate brain tumor classification is crucial for enhancing the diagnosis, prognosis, and treatment of glioblastoma patients. We employed the ResNet101 deep learning method with transfer learning to analyze the 2021 Radiological Society of North America (RSNA) Brain Tumor challenge dataset. This dataset comprises four structural magnetic resonance imaging (MRI) sequences: fluid‐attenuated inversion‐recovery (FLAIR), T1‐weighted pre‐contrast (T1w), T1‐weighted post‐contrast (T1Gd), and T2‐weighted (T2). We assessed the model's performance using standard evaluation metrics. The highest performance to detect MGMT methylation status for patients suffering glioblastoma was an accuracy (85.48%), sensitivity (80.64%), specificity (90.32%). Whereas classification performance with no tumor was yielded with accuracy (85.48%), sensitivity (90.32%), specificity (80.64%). The radiomic features (74) computed with ensembled Bagged Tree and relief feature selection method (30/74) improved the validation accuracy of 84.3% and AUC of 0.9038 to detect. O6‐methylguanine‐DNA methyltransferase (MGMT) promoter methylation status in glioblastoma patients holds promise for optimizing treatment planning and prognosis. By understanding MGMT methylation status, clinicians can make informed decisions about treatment strategies, potentially leading to improved clinical outcomes.